Il Dong Pharmaceutical Co Ltd (249420) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Il Dong Pharmaceutical Co Ltd (249420) has a cash flow conversion efficiency ratio of 0.050x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩11.28 Billion ≈ $7.65 Million USD) by net assets (₩226.84 Billion ≈ $153.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Il Dong Pharmaceutical Co Ltd (249420) liquidity interval to measure how many days the company can operate on defensive assets alone.
Il Dong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Il Dong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Il Dong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Il Dong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Jinfei Kaida Wheel Co Ltd
SHE:002863
|
0.040x |
|
Neurogene Inc
NASDAQ:NGNE
|
-0.110x |
|
Sichuan Tianwei Electronic Co Ltd
SHG:688511
|
-0.013x |
|
Apartment Investment and Management Co
NYSE:AIV
|
0.005x |
|
Weltrend Semiconductor Inc
TW:2436
|
0.038x |
|
Bahnhof AB Series B
ST:BAHN-B
|
0.072x |
|
Tsogo Sun
JSE:TSG
|
0.196x |
|
DIAMOND BIOFUND INC
TW:6901
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Il Dong Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Il Dong Pharmaceutical Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Il Dong Pharmaceutical Co Ltd (249420) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩159.06 Billion ≈ $107.79 Million |
₩28.29 Billion ≈ $19.17 Million |
0.178x | +184.66% |
| 2023-12-31 | ₩174.27 Billion ≈ $118.10 Million |
₩-36.62 Billion ≈ $-24.81 Million |
-0.210x | +22.21% |
| 2022-12-31 | ₩198.22 Billion ≈ $134.33 Million |
₩-53.54 Billion ≈ $-36.28 Million |
-0.270x | -281.61% |
| 2021-12-31 | ₩160.58 Billion ≈ $108.83 Million |
₩-11.37 Billion ≈ $-7.70 Million |
-0.071x | -193.03% |
| 2020-12-31 | ₩254.55 Billion ≈ $172.50 Million |
₩19.37 Billion ≈ $13.12 Million |
0.076x | -53.49% |
| 2019-12-31 | ₩252.89 Billion ≈ $171.38 Million |
₩41.37 Billion ≈ $28.03 Million |
0.164x | -32.06% |
| 2018-12-31 | ₩276.82 Billion ≈ $187.60 Million |
₩66.65 Billion ≈ $45.17 Million |
0.241x | -6.91% |
| 2017-12-31 | ₩285.07 Billion ≈ $193.19 Million |
₩73.72 Billion ≈ $49.96 Million |
0.259x | +50.98% |
| 2016-12-31 | ₩268.41 Billion ≈ $181.90 Million |
₩45.98 Billion ≈ $31.16 Million |
0.171x | -- |
About Il Dong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central n… Read more